Drugs of abuse arrays improve efficiency and reduce costs through high throughput screening, simple sample preparation, reduced sample and reagent volumes and multi-analyte reagents and controls
Drugs of abuse testing can be costly and time-consuming, and may not always include all common drugs and their metabolites.
There is a need to find rapid and cost-effective methods to screen for drugs of abuse.
Randox has developed two drugs of abuse (DoA) biochip arrays that each simultaneously screen for ten drugs in a small sample.
DoA array I tests for barbiturates, amphetamines, cocaine, opiates and cannabinoids.
DoA array II screens for six opioid analgesics including Fentanyl, as well as Ketamine, LSD, Methaqualone and Ecstasy (MDMA).
Performed as competitive immunoassays, both biochips have the unique feature of simultaneously testing for parent drugs and their metabolites in a single sample.
Separate biochips are available for different matrices: blood, urine and oral fluid.
The urine arrays also include creatinine to identify adulterated urine samples.
The biochips offer the platform for simultaneous testing of all drugs of abuse analytes.
Three analysers embrace the technology.
The fully automated Evidence Analyser offers a rapid, consistent and cost-effective system for high-throughput drugs of abuse screening.
The semi-automated Evidence Investigator is designed for low-throughput screening and research applications.
The Evidence MultiStat, available later in the year, is a point-of-application analyser for results in 20 minutes.
Randox says it has taken drugs of abuse screening to the next level through simultaneous multi-analyte testing.
